Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Selective elimination of mast cells via Siglec-6-targeted nanodelivery of drug payload.
Journal: The Journal of allergy and clinical immunology
Published: May 18, 2025
Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells.
Journal: Frontiers in immunology
Published: August 25, 2023
A Cell-Free Protein Synthesis Platform to Produce a Clinically Relevant Allergen Panel.
Journal: ACS synthetic biology
Published: August 08, 2023
Functional and Phenotypic Characterization of Siglec-6 on Human Mast Cells.
Journal: Cells
Published: February 28, 2022
Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro.
Journal: Frontiers in immunology
Published: July 08, 2021
Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.
Journal: Journal of leukocyte biology
Published: November 26, 2019
Single-site, five-year experience with human eosinophil isolation by density gradient centrifugation and CD16 immunomagnetic negative separation.
Journal: BMC research notes
Published: October 12, 2019
Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.
Journal: The Journal of allergy and clinical immunology
Published: April 20, 2018
Frontline Science: Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils.
Journal: Journal of leukocyte biology
Published: September 29, 2017
Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating β2-integrin-dependent function in human eosinophils.
Journal: The Journal of allergy and clinical immunology
Published: February 24, 2017
Granulocyte colony-stimulating factor blockade enables dexamethasone to inhibit lipopolysaccharide-induced murine lung neutrophils.
Journal: PloS one
Published: January 14, 2017
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Journal: The Journal of allergy and clinical immunology
Published: December 16, 2016
Last Updated: 09/26/2026